TWI564305B - 治療性抗體 - Google Patents

治療性抗體 Download PDF

Info

Publication number
TWI564305B
TWI564305B TW101120198A TW101120198A TWI564305B TW I564305 B TWI564305 B TW I564305B TW 101120198 A TW101120198 A TW 101120198A TW 101120198 A TW101120198 A TW 101120198A TW I564305 B TWI564305 B TW I564305B
Authority
TW
Taiwan
Prior art keywords
antibody
seq
sequence
human
antibodies
Prior art date
Application number
TW101120198A
Other languages
English (en)
Chinese (zh)
Other versions
TW201311724A (zh
Inventor
史戴方 蒼
路易斯 海傑瑞德 卓森
安克 瓊 漢森
克里斯堤恩 克潔賈德
斯倫 朗德
Original Assignee
諾佛 儂迪克股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 諾佛 儂迪克股份有限公司 filed Critical 諾佛 儂迪克股份有限公司
Publication of TW201311724A publication Critical patent/TW201311724A/zh
Application granted granted Critical
Publication of TWI564305B publication Critical patent/TWI564305B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
TW101120198A 2011-06-06 2012-06-06 治療性抗體 TWI564305B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11168787 2011-06-06
US201161505137P 2011-07-07 2011-07-07
EP12159172 2012-03-13

Publications (2)

Publication Number Publication Date
TW201311724A TW201311724A (zh) 2013-03-16
TWI564305B true TWI564305B (zh) 2017-01-01

Family

ID=47295509

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101120198A TWI564305B (zh) 2011-06-06 2012-06-06 治療性抗體

Country Status (16)

Country Link
US (7) US8613926B2 (enExample)
EP (3) EP3424953B1 (enExample)
JP (2) JP6141834B2 (enExample)
KR (1) KR101978757B1 (enExample)
CN (1) CN103596982B (enExample)
AU (1) AU2012266487B2 (enExample)
BR (1) BR112013031198B1 (enExample)
CA (1) CA2838497C (enExample)
DK (3) DK3798230T3 (enExample)
ES (2) ES2693647T3 (enExample)
IL (1) IL229254A (enExample)
PL (2) PL3424953T3 (enExample)
PT (1) PT3424953T (enExample)
RU (1) RU2616881C2 (enExample)
TW (1) TWI564305B (enExample)
WO (1) WO2012168199A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3424953T3 (pl) 2011-06-06 2021-01-25 Novo Nordisk A/S Lecznicze przeciwciała
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
ES2927567T3 (es) 2013-09-13 2022-11-08 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
EP3626748A1 (en) * 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
EP3171892B1 (en) 2014-07-22 2021-11-24 Apollomics Inc. Anti-pd-1 antibodies
CN110964108B (zh) 2014-08-05 2023-07-07 中美冠科生物技术（太仓）有限公司 抗pd-l1抗体
US20170328898A1 (en) * 2014-10-31 2017-11-16 Cell Trend GmbH Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor
ES2909973T3 (es) * 2015-11-04 2022-05-10 Hope City Receptores quiméricos para el antígeno que se dirigen a HER2
AU2016359790A1 (en) * 2015-11-23 2018-06-21 Innate Pharma CD39 vascular isoform targeting agents
MX2018006385A (es) 2015-11-25 2019-09-11 Visterra Inc Moleculas de anticuerpo contra april y usos de las mismas.
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
KR102218714B1 (ko) 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
CA3034326A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
JP7762498B2 (ja) * 2017-05-25 2025-10-30 ブリストル－マイヤーズ スクイブ カンパニー 修飾重鎖定常領域を含む抗体
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
WO2019092148A1 (en) * 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
AU2019289646B2 (en) 2018-06-18 2025-10-23 Innate Pharma Compositions and methods for treating cancer
IL281594B1 (en) 2018-09-17 2025-10-01 Abcuro Inc Antibodies against KLRG1
US20220041719A1 (en) * 2018-12-05 2022-02-10 Morphosys Ag Multispecific antigen-binding molecules
KR20210141988A (ko) * 2019-03-14 2021-11-23 모르포시스 아게 C5ar을 표적으로 하는 항체
MX2022006670A (es) * 2019-12-03 2023-03-17 Shanghai Jiao Tong Univ School Of Medicine Region fc de anticuerpo teniendo mayor afinidad de union al fcyriib.
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
WO2022033981A1 (en) 2020-08-12 2022-02-17 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
US20230374147A1 (en) 2020-11-02 2023-11-23 Hummingbird Bioscience Pte. Ltd. Bcma/taci antigen-binding molecules
EP4277931A1 (en) 2021-01-13 2023-11-22 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
MX2023010567A (es) 2021-03-12 2023-09-21 Genmab As Variantes de anticuerpos no activadoras.
TW202328196A (zh) 2021-09-16 2023-07-16 新加坡商蜂鳥生物科技私人有限公司 使用vista抗原結合分子的癌症之治療及預防
WO2023046979A1 (en) 2021-09-27 2023-03-30 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
IL311805A (en) 2021-10-08 2024-05-01 Genmab As Antibodies that bind to CD30 and CD3
US20250145730A1 (en) * 2021-12-16 2025-05-08 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-immunoglobulin degrading enzyme-digested fc variant
TW202409280A (zh) 2022-07-08 2024-03-01 新加坡科技研究局 Cnx抗原結合分子
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
WO2024062073A1 (en) 2022-09-22 2024-03-28 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
EP4646233A1 (en) 2023-01-03 2025-11-12 Hummingbird Bioscience Pte. Ltd. Her3-binding antibody-drug conjugate
WO2024146959A1 (en) 2023-01-06 2024-07-11 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
CN121002069A (zh) 2023-01-06 2025-11-21 泰温治疗私人有限公司 抗原结合分子
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2025125495A1 (en) 2023-12-13 2025-06-19 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
WO2025133322A1 (en) 2023-12-22 2025-06-26 Agency For Science, Technology And Research Cnx antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2025257350A1 (en) 2024-06-13 2025-12-18 Singapore Health Services Pte Ltd Pai-1 antigen-binding molecules
EP4670793A1 (en) 2024-06-24 2025-12-31 Montis Biosciences BV C1Q ANTIGEN BINDING MOLECULES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506237A (zh) * 2006-08-22 2009-08-12 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1550729B1 (en) 1992-09-25 2009-05-27 Avipep Pty Limited Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
US20010036650A1 (en) 1994-08-16 2001-11-01 Human Genome Sciences, Inc. C5a receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU718311B2 (en) 1995-06-05 2000-04-13 Incyte Pharmaceuticals, Inc. A C5a-like seven transmembrane receptor
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
JP2001511645A (ja) 1997-01-31 2001-08-14 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトＣ５ａ様受容体
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU2002231194A1 (en) 2000-11-07 2002-05-21 Genetics Institute, Llc G protein-coupled receptor protein and nucleic acid molecules and uses therefor
EP1409646B1 (en) 2000-12-19 2012-06-13 Altor BioScience Corporation Transgenic animals comprising a humanized immune system
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
CN100391537C (zh) 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
EP1438325B1 (en) 2001-09-27 2009-12-30 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP2371861B1 (en) 2002-01-25 2017-08-09 Novo Nordisk A/S Monoclonal antibodies against extracellular loops of C5aR
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
AU2002952086A0 (en) 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
EP1606621B1 (en) 2003-03-17 2008-10-29 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
EP1701611B1 (en) 2003-12-24 2011-05-18 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
EP1586583A3 (en) 2004-04-16 2005-11-16 Alligator Bioscience AB (publ) Compounds that block C5a complement receptor and their use in therapy
IL316252A (en) * 2005-03-23 2024-12-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
CN101501073A (zh) 2006-08-22 2009-08-05 G2英弗勒美欣私人有限公司 抗体制备方法
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
AU2008314697B2 (en) * 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
CN101970494B (zh) 2008-02-20 2015-01-21 G2炎症私人有限公司 人源化抗-C5aR抗体
US9040507B2 (en) 2008-06-02 2015-05-26 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
CN102264227B (zh) * 2008-12-22 2014-07-23 凯莫森特里克斯股份有限公司 C5aR拮抗剂
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CA2789061A1 (en) 2010-02-26 2011-09-01 Henrik Parshad Stable antibody containing compositions
BR112012030139A2 (pt) 2010-05-28 2017-06-13 Novo Nordisk As composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante
WO2012001087A1 (en) * 2010-06-30 2012-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
US20130183280A1 (en) * 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
CA2822288A1 (en) * 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
PL3424953T3 (pl) * 2011-06-06 2021-01-25 Novo Nordisk A/S Lecznicze przeciwciała
CN105392803B (zh) 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506237A (zh) * 2006-08-22 2009-08-12 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Strohl, W.," Optimization of Fc-Mediated Effector Functions of Monoclonal Antibodies", Curr. Opin. Biotechnol., 2009, Vol.20, Issue 6, P.685-691. *

Also Published As

Publication number Publication date
IL229254A0 (en) 2014-01-30
DK2718322T3 (en) 2018-12-03
CA2838497A1 (en) 2012-12-13
PL3424953T3 (pl) 2021-01-25
ES2929575T3 (es) 2022-11-30
KR20140036261A (ko) 2014-03-25
US20200017599A1 (en) 2020-01-16
PL2718322T3 (pl) 2019-07-31
EP3424953B1 (en) 2020-08-05
US10323097B2 (en) 2019-06-18
US20130004514A1 (en) 2013-01-03
PT3424953T (pt) 2020-11-03
EP2718322B1 (en) 2018-08-08
DK3798230T3 (en) 2022-10-31
JP6141834B2 (ja) 2017-06-07
TW201311724A (zh) 2013-03-16
BR112013031198A2 (pt) 2016-11-29
CA2838497C (en) 2023-02-28
BR112013031198A8 (pt) 2018-01-16
US20240218076A1 (en) 2024-07-04
EP3798230A1 (en) 2021-03-31
ES2693647T3 (es) 2018-12-13
CN103596982B (zh) 2016-11-02
US20170073421A1 (en) 2017-03-16
AU2012266487B2 (en) 2016-12-08
US20150044231A1 (en) 2015-02-12
RU2616881C2 (ru) 2017-04-18
IL229254A (en) 2017-09-28
US10882916B2 (en) 2021-01-05
US20210238300A1 (en) 2021-08-05
US8846045B2 (en) 2014-09-30
RU2013155029A (ru) 2015-07-20
BR112013031198B1 (pt) 2020-10-20
KR101978757B1 (ko) 2019-05-15
US20130295116A1 (en) 2013-11-07
WO2012168199A1 (en) 2012-12-13
EP3798230B1 (en) 2022-08-03
AU2012266487A1 (en) 2013-11-21
EP3424953A1 (en) 2019-01-09
JP6416177B2 (ja) 2018-10-31
JP2014523408A (ja) 2014-09-11
EP2718322A1 (en) 2014-04-16
CN103596982A (zh) 2014-02-19
JP2017081941A (ja) 2017-05-18
US8613926B2 (en) 2013-12-24
DK3424953T3 (en) 2020-11-02

Similar Documents

Publication Publication Date Title
TWI564305B (zh) 治療性抗體
US11680097B2 (en) Antibodies against canine PD-1
US11993658B2 (en) Anti-BCMA antibodies and treatment methods
CN116981477A (zh) 抗masp2抗体、其抗原结合片段及医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2022022662A1 (zh) Cd47抗体及其应用
CA3239307A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
ES2831303T3 (es) Anticuerpos terapéuticos
WO2023283211A2 (en) Cd21 antibodies and uses thereof
MX2013013911A (es) Anticuerpos terapeuticos.